Stock listing
ASX:BDX BCAL Diagnostics Limited Share Price
Follow BCAL Diagnostics Limited into a list and get an email when it puts out news.
Share price · ASX:BDX
$0.06 AUD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.06 – $0.06 AUDNov 20, 2026
- Volume
- 69 sharesNov 20, 2026
- Market cap
- $22.12M AUDAt the close on Nov 20, 2026 · price × 368.7M shares outstanding
- 52-week range
- $0.052 – $0.155 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $8,905 AUDMedian day 38,002 shares · 11 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:BDX · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.06 | 0.00 | 0.0% | $0.06 | $0.06 | $0.06 | 69 | |
| $0.06 | 0.00 | 0.0% | $0.06 | $0.06 | $0.06 | 840 | |
| $0.06 | 0.00 | 0.0% | $0.06 | $0.06 | $0.059 | 61,581 | |
| $0.06 | 0.00 | 0.0% | $0.06 | $0.06 | $0.06 | 0 | |
| $0.06 | -0.001 | -1.6% | $0.062 | $0.065 | $0.06 | 17,209 | |
| $0.061 | -0.003 | -4.7% | $0.061 | $0.061 | $0.058 | 11,500 | |
| $0.064 | 0.00 | 0.0% | $0.064 | $0.064 | $0.064 | 0 | |
| $0.064 | -0.004 | -5.9% | $0.064 | $0.064 | $0.064 | 5,140 | |
| $0.068 | +0.001 | +1.5% | $0.068 | $0.069 | $0.068 | 11,408 | |
| $0.067 | +0.002 | +3.1% | $0.063 | $0.067 | $0.063 | 107,339 | |
| $0.065 | +0.011 | +20.4% | $0.055 | $0.065 | $0.055 | 349,353 | |
| $0.054 | -0.016 | -22.9% | $0.067 | $0.067 | $0.053 | 329,597 | |
| $0.07 | -0.012 | -14.6% | $0.07 | $0.07 | $0.07 | 7,500 | |
| $0.082 | -0.002 | -2.4% | $0.082 | $0.082 | $0.082 | 129 | |
| $0.084 | +0.004 | +5.0% | $0.084 | $0.084 | $0.084 | 48 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 3,353 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.08 | $0.08 | 0 | |
| $0.08 | +0.005 | +6.7% | $0.075 | $0.081 | $0.075 | 46,647 | |
| $0.075 | 0.00 | 0.0% | $0.075 | $0.075 | $0.075 | 39,054 | |
| $0.075 | -0.003 | -3.8% | $0.078 | $0.078 | $0.075 | 65,286 | |
| $0.078 | -0.001 | -1.3% | $0.079 | $0.079 | $0.078 | 22,657 | |
| $0.079 | 0.00 | 0.0% | $0.082 | $0.082 | $0.079 | 1,560 | |
| $0.079 | 0.00 | 0.0% | $0.079 | $0.079 | $0.079 | 0 | |
| $0.079 | 0.00 | 0.0% | $0.079 | $0.079 | $0.079 | 0 | |
| $0.079 | -0.001 | -1.3% | $0.079 | $0.079 | $0.079 | 45,129 | |
| $0.08 | -0.01 | -11.1% | $0.085 | $0.085 | $0.079 | 81,498 | |
| $0.09 | -0.001 | -1.1% | $0.091 | $0.091 | $0.09 | 882,246 | |
| $0.091 | +0.001 | +1.1% | $0.09 | $0.091 | $0.09 | 10,372 | |
| $0.09 | 0.00 | 0.0% | $0.09 | $0.091 | $0.09 | 104,931 | |
| $0.09 | -0.004 | -4.3% | $0.09 | $0.09 | $0.09 | 33,298 | |
| $0.094 | +0.001 | +1.1% | $0.094 | $0.094 | $0.09 | 31,194 | |
| $0.093 | +0.002 | +2.2% | $0.09 | $0.093 | $0.09 | 502,259 | |
| $0.091 | +0.004 | +4.6% | $0.09 | $0.091 | $0.09 | 66,163 | |
| $0.087 | -0.003 | -3.3% | $0.092 | $0.092 | $0.087 | 360,690 | |
| $0.09 | 0.00 | 0.0% | $0.091 | $0.091 | $0.087 | 721,729 | |
| $0.09 | +0.009 | +11.1% | $0.083 | $0.09 | $0.083 | 195,868 | |
| $0.081 | -0.004 | -4.7% | $0.081 | $0.081 | $0.081 | 95,228 | |
| $0.085 | +0.004 | +4.9% | $0.085 | $0.085 | $0.085 | 1,155 | |
| $0.081 | -0.004 | -4.7% | $0.082 | $0.082 | $0.08 | 231,833 | |
| $0.085 | +0.003 | +3.7% | $0.082 | $0.085 | $0.08 | 476,737 | |
| $0.082 | 0.00 | 0.0% | $0.085 | $0.085 | $0.082 | 81,446 | |
| $0.082 | -0.004 | -4.7% | $0.08 | $0.083 | $0.08 | 269,840 | |
| $0.086 | 0.00 | 0.0% | $0.086 | $0.086 | $0.086 | 0 | |
| $0.086 | 0.00 | 0.0% | $0.086 | $0.086 | $0.08 | 233,423 | |
| $0.086 | +0.016 | +22.9% | $0.077 | $0.086 | $0.077 | 265,690 | |
| $0.07 | -0.001 | -1.4% | $0.071 | $0.071 | $0.07 | 125,576 | |
| $0.071 | 0.00 | 0.0% | $0.071 | $0.071 | $0.071 | 0 | |
| $0.071 | -0.004 | -5.3% | $0.074 | $0.074 | $0.071 | 38,658 | |
| $0.075 | -0.001 | -1.3% | $0.072 | $0.075 | $0.072 | 6,995 | |
| $0.076 | +0.011 | +16.9% | $0.065 | $0.077 | $0.065 | 180,266 | |
| $0.065 | 0.00 | 0.0% | $0.065 | $0.065 | $0.065 | 0 | |
| $0.065 | -0.002 | -3.0% | $0.067 | $0.067 | $0.065 | 203,109 | |
| $0.067 | -0.002 | -2.9% | $0.07 | $0.07 | $0.067 | 10,148 | |
| $0.069 | 0.00 | 0.0% | $0.066 | $0.069 | $0.066 | 40,610 | |
| $0.069 | +0.001 | +1.5% | $0.069 | $0.069 | $0.069 | 14,492 | |
| $0.068 | +0.003 | +4.6% | $0.065 | $0.068 | $0.065 | 67,478 | |
| $0.065 | -0.001 | -1.5% | $0.066 | $0.066 | $0.065 | 31,785 | |
| $0.066 | 0.00 | 0.0% | $0.067 | $0.07 | $0.065 | 183,420 | |
| $0.066 | +0.006 | +10.0% | $0.065 | $0.066 | $0.065 | 37,346 | |
| $0.06 | -0.002 | -3.2% | $0.061 | $0.061 | $0.057 | 209,586 | |
| $0.062 | +0.01 | +19.2% | $0.06 | $0.07 | $0.06 | 351,027 | |
| $0.052 | 0.00 | 0.0% | $0.052 | $0.052 | $0.052 | 0 | |
| $0.052 | -0.006 | -10.3% | $0.059 | $0.059 | $0.052 | 157,521 | |
| $0.058 | +0.002 | +3.6% | $0.058 | $0.058 | $0.058 | 11,072 | |
| $0.056 | 0.00 | 0.0% | $0.056 | $0.056 | $0.056 | 0 |
- Ticker
- ASX:BDX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 19, 2026
BCAL Position on GSS-MAP Merger
Latest deck · Oct 19, 2026
Shareholder Meeting (October 2026)
Shareholder meeting · 19 slides
Latest news
BCAL Position on GSS-MAP Merger
Nov 18, 2026
Closed $0.06 (0.0%) on Nov 20, 2026
Notification regarding unquoted securities - BDX
Nov 17, 2026
Closed $0.06 (0.0%) on Nov 18, 2026
Change of Director's Interest Notice
Nov 17, 2026
Closed $0.06 (0.0%) on Nov 18, 2026
BCAL Expands Breast Cancer Biomarker Program
Nov 16, 2026
Closed $0.06 (0.0%) on Nov 17, 2026
Notification of cessation of securities - BDX
Nov 13, 2026
Closed $0.06 (0.0%) on Nov 16, 2026
Application for quotation of securities - BDX
Nov 13, 2026
Closed $0.06 (0.0%) on Nov 16, 2026
GSS - Panel Receives Application
Nov 13, 2026
Closed $0.06 (0.0%) on Nov 16, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 29, 2026
Closed $0.084 (+5.0%) on Oct 30, 2026
BCAL Welcomes Dr John Melki's Appointment to GSS Board
Oct 28, 2026
Closed $0.08 (0.0%) on Oct 29, 2026
Results of Meeting
Oct 18, 2026
Closed $0.079 (0.0%) on Oct 19, 2026
BCAL Diagnostics Limited on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 46 in the last 12 months · 78 in all · newest Nov 19, 2026 · oldest 2021
- Decks
- 19 decks · latest Oct 19, 2026
Valuation
EV/sales 150× against a median of 1.8×: 10th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $27.45M AUD
- P/E
- Loss
- EV/sales
- 150×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- −293.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BCAL Diagnostics Limited · ASX:BDX | US$14.64M | US$18.17M | n/a | 150× | n/a | n/a | n/a | n/a | n/a |
| PlexBio Co., Ltd. · TPEX:6572 | US$15.79M | US$7.19M | n/a | 1.9× | n/a | 1.8× | −49.1% | 0.0× | n/a |
| Biosynex SA · EURONEXT:ALBIO | US$15.37M | US$73.75M | n/a | 0.7× | 2.3× | 0.4× | −61.1% | 1.9× | n/a |
| Verici DX PLC · LSE:VRCI | US$15.25M | US$13.61M | n/a | 3.6× | n/a | 2.6× | −189.2% | 0.1× | n/a |
| Medicon Hellas · ATHEX:MEDIC | US$14.99M | US$7.66M | 7.7× | 0.4× | 1.9× | 0.7× | 9.8% | 0.0× | n/a |
| Pharmigene, Inc. · TPEX:7595 | US$14.70M | US$29.38M | n/a | 4.8× | n/a | 1.9× | −36.5% | 2.2× | n/a |
| Rhythm Biosciences Limited · ASX:RHY | US$14.05M | US$11.94M | n/a | 211× | n/a | 5.8× | n/a | 0.1× | n/a |
| Noul Co Ltd. · KRX:376930 | US$14.03M | US$6.23M | n/a | 1.6× | n/a | 1.1× | −389.6% | 0.0× | n/a |
| Telescope Innovations Corp · CSE:TELI | US$13.52M | US$12.59M | n/a | 2.5× | n/a | 5.7× | −56.0% | 0.0× | 1.20 |
| LabGenomics Co., Ltd. · KRX:084650 | US$13.28M | US$2.59M | n/a | 0.0× | n/a | 0.1× | −66.5% | 0.1× | n/a |
| IDT Australia Limited · ASX:IDT | US$13.09M | US$18.52M | n/a | 1.4× | n/a | 1.0× | −13.4% | 0.6× | n/a |
| Median of the others | US$14.38M | US$12.27M | 7.7× | 1.8× | 2.0× | 1.5× | −56.0% | 0.1× | 1.20 |
Team and board
Officers
| Officer | Role |
|---|---|
| Anne-Louise Arnett | Chief Executive Officer |
| Guy Robertson | Chief Financial Officer & Company Secretary |
| Jayne Shaw | Co-Founder and Executive Chair |
| Kathy Koskiris | Director of Clinical Laboratory Services |
| Michelle Blackwell | Chief Product Innovation Officer |
Board
| Director | Role |
|---|---|
| Jayne Shaw | Co-Founder and Executive Chair |
| David Darling | Non-Executive Director |
| John Hurrell | Non-Executive Director and Consultant |
| Jonathan Trollip | Independent Non-Executive Director |
| Mark McConnell | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 28, 2025 | −6.3% |
| Q4 2024 | Feb 27, 2025 | −10.0% |
| Q4 2022 | Feb 23, 2023 | 0.0% |
| Q2 2022 | Aug 29, 2022 | −3.8% |
| Q4 2021 | Feb 17, 2022 | −3.9% |
| Q2 2021 | Jul 19, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (October 2026) | Shareholder meeting | 19 slides | Oct 19, 2026 |
| Investor Presentation (October 2026) | Investor deck | 14 slides | Oct 6, 2026 |
| FY2026 Earnings Presentation | Earnings | 29 slides | September 2026 |
| 20th Bioshares Biotech Summit 2026 | Conference | 18 slides | Aug 6, 2026 |
| H1 FY2026 Earnings Presentation | Earnings | 18 slides | February 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 31 slides | November 2025 |
| Corporate Update (September 2025) | Corporate update | 11 slides | September 2025 |
| Investor Presentation (March 2025) | Investor deck | 32 slides | Mar 24, 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 21 slides | Nov 22, 2024 |
| Spark+ Australian Equities Day (September 2024) | Conference | 24 slides | September 2024 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 18th Bioshares Biotech Summit 2024 | Conference | 21 slides | Jul 11, 2024 |
| JMM & Ethica Capital - Innovation & Investment Insights (May 2024) | Conference | 16 slides | May 2, 2024 |
| Investor Presentation (March 2024) | Investor deck | 26 slides | Mar 6, 2024 |
| Shareholder Meeting (November 2023) | Shareholder meeting | 35 slides | Nov 22, 2023 |
| Corporate Update (August 2023) | Corporate update | 27 slides | Aug 8, 2023 |
| Investor Presentation (August 2023) | Investor deck | 32 slides | August 2023 |
| Shareholder Meeting (November 2022) | Shareholder meeting | 22 slides | Nov 30, 2022 |
| Shareholder Meeting (November 2021) | Shareholder meeting | 28 slides | November 2021 |
| Investor Presentation (July 2021) | Investor deck | 28 slides | Jul 21, 2021 |
Financings
| Raise | Date |
|---|---|
| Convertible notes Tranche closed: A$1 Insiders: Shareholders approved the issue of 1,000,000 Convertible Notes and up to 10,367,098 Shares on conversion to a related party | Nov 18, 2026 |
| Convertible Notes Update: convertible Use of proceeds: Develop and commercialise its blood-based early cancer detection portfolio and support planned activities through FY2027 | Jun 29, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 182.5K | 21.6K | 3.10M | 2.79M | 718.7K | 275.3K | 442.1K | 258.2K | 242.3K |
| Cost of revenue | 717.2K | 579.8K | 113.6K | 20.6K | 7.73K | 3.55K | 14.0K | ||
| Gross profit | -534.7K | 21.6K | 3.10M | 2.79M | 698.1K | 275.3K | 434.4K | 254.7K | 228.2K |
| Research and development | 4.67M | 1.57M | 4.36M | 4.47M | 1.91M | 664.1K | 466.8K | 205.4K | 251.9K |
| Selling, general and administrative | 5.13M | 5.12M | 1.64M | 2.35M | 1.87M | 249.0K | 176.9K | 136.9K | 144.3K |
| Operating income | -9.39M | -9.96M | -5.45M | -4.67M | -3.03M | -1.80M | -1.14M | -683.1K | -704.3K |
| Depreciation and amortization | 717.2K | 1.00M | 579.8K | 113.6K | 20.6K | 7.73K | 7.73K | 3.55K | 14.0K |
| EBITDA | -8.67M | -8.96M | -4.87M | -4.56M | -3.01M | -1.79M | -1.13M | -679.5K | -690.3K |
| Interest expense | 346.6K | 92.0K | 99.9K | 16.0K | 0 | 0 | 0 | 5.10K | 5.63K |
| Income before tax | -9.54M | -7.24M | -9.45M | -5.06M | -3.39M | -1.80M | -1.04M | -686.5K | -708.8K |
| Income tax | -2.17M | -2.63M | -3.05M | -2.79M | -700.0K | -275.0K | -342.0K | -256.5K | -241.2K |
| Net income | -7.37M | -7.24M | -6.40M | -5.06M | -3.39M | -1.52M | -696.4K | -430.0K | -467.6K |
| Earnings per share, basic | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | -0.00 | -0.00 | -0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.59M | 4.52M | 6.47M | 3.17M | 5.57M | 3.41M | 416.2K | 276.6K | 309.1K |
| Short-term investments | 0 | 4.00M | |||||||
| Receivables | 2.38M | 6.93K | 34.6K | 1.11K | 793.3K | 352.6K | 403.3K | 259.3K | 250.4K |
| Inventory | -2.70M | 3.03M | 780.2K | -403.3K | -259.3K | -250.4K | |||
| Current assets | 4.07M | 7.20M | 9.34M | 6.20M | 10.5M | 4.13M | 819.6K | 536.0K | 559.5K |
| Property, plant and equipment | 2.71M | 2.93M | 2.17M | 135.2K | 3.85K | 0 | 3.92K | 0 | |
| Total assets | 7.66M | 9.91M | 12.3M | 8.37M | 10.6M | 4.13M | 819.6K | 540.3K | 560.0K |
| Accounts payable | 630.7K | 548.4K | 740.2K | 1.58M | 277.2K | 250.7K | 60.0K | 2.06K | 77.6K |
| Current liabilities | 3.00M | 3.11M | 2.60M | 2.26M | 950.4K | 525.6K | 80.6K | 52.1K | 141.9K |
| Long-term debt | 4.94M | 122.1K | 400.2K | 0 | 0 | 300.0K | 0 | 500.0K | |
| Total debt | 6.92M | 2.38M | 1.52M | 1.06M | 300.0K | 500.0K | |||
| Total liabilities | 8.49M | 3.69M | 3.68M | 3.16M | 950.4K | 525.6K | 380.6K | 52.1K | 641.9K |
| Shareholders' equity | -826.2K | 6.22M | 8.59M | 5.21M | 9.64M | 3.61M | 438.9K | 488.2K | -81.8K |
| Shares outstanding | 367.6M | 359.6M | 246.2M | 210.9M | 204.3M | 215.1M | 215.1M | 215.1M | 215.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.16M | -6.14M | -4.52M | -6.05M | -3.22M | -1.21M | -661.7K | -525.0K | -470.8K |
| Capital spending | -459.0K | -787.7K | -1.15M | -362.5K | -4.03M | -3.85K | -3.81K | -7.47K | -14.0K |
| Free cash flow | -6.62M | -6.92M | -5.67M | -6.41M | -7.25M | -1.21M | -665.5K | -532.5K | -484.8K |
| Cash from investing | -1.44M | -787.7K | -1.15M | 3.64M | -4.03M | -3.85K | -3.81K | -7.47K | -14.1K |
| Cash from financing | 4.66M | 4.97M | 8.97M | 13.2K | 9.41M | 4.20M | 805.0K | 500.0K | 500.0K |
| Share buybacks | -115.0K | -444.8K | 50.0K | -621.8K | 4.41M | 505.0K | 500.0K | 0 | |
| Change in cash | -2.94M | -1.95M | 3.30M | -2.40M | 2.16M | 2.99M | 139.6K | -32.5K | 15.1K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| BCAL Position on GSS-MAP Merger | Nov 18, 2026 | Acquisition or disposal | ASX |
| Notification regarding unquoted securities - BDX | Nov 17, 2026 | Other filings | ASX |
| Change of Director's Interest Notice | Nov 17, 2026 | Ownership change notice | ASX |
| BCAL Expands Breast Cancer Biomarker Program | Nov 16, 2026 | Operations update | ASX |
| Notification of cessation of securities - BDX | Nov 13, 2026 | Financing | ASX |
| Notification of cessation of securities - BDX | Nov 13, 2026 | Financing | ASX |
| Application for quotation of securities - BDX | Nov 13, 2026 | Financing | ASX |
| GSS - Panel Receives Application | Nov 13, 2026 | Other filings | ASX |
| Change of Director's Interest Notice | Nov 10, 2026 | Ownership change notice | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
All 78 filings
Cap table
Built by 6ix from BCAL Diagnostics Limited’s releases · as of Nov 18, 2026
- Common shares
- 368,683,291
- Fully diluted
- 368,683,291
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 368,683,291 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 368,683,291 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anne-Louise Arnett | Chief Executive Officer · Since at least May 11, 2026 |
| David Darling | Non-Executive Director · Since at least Nov 5, 2026 |
| Guy Robertson | Chief Financial Officer & Company Secretary · Since at least Nov 5, 2026 |
| Jayne Shaw | Co-Founder and Executive Chair · Since at least Sep 3, 2026 |
| John Hurrell | Non-Executive Director and Consultant · Since at least Nov 5, 2026 |
| Jonathan Trollip | Independent Non-Executive Director · Since at least Nov 5, 2026 |
| Kathy Koskiris | Director of Clinical Laboratory Services · Since at least Nov 4, 2026 |
| Mark McConnell | Non-Executive Director · Since at least Nov 5, 2026 |
| Michelle Blackwell | Chief Product Innovation Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about BCAL Diagnostics Limited.